3.39 USD
+0.07 (+2.11%)
At close: Feb 10, 2026
3.3701 USD
-0.02 (-0.59%)
After Hours: 2/10/2026, 7:03:29 PM
Overall ESPR gets a fundamental rating of 2 out of 10. We evaluated ESPR against 191 industry peers in the Pharmaceuticals industry. ESPR may be in some trouble as it scores bad on both profitability and health. ESPR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ESPR has reported negative net income.
- In the past year ESPR has reported a negative cash flow from operations.
- ESPR had negative earnings in each of the past 5 years.
- In the past 5 years ESPR always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -29.07%, ESPR perfoms like the industry average, outperforming 52.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ESPR has a better Gross Margin (58.20%) than 69.11% of its industry peers.
- ESPR's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for ESPR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ESPR has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ESPR has been increased compared to 5 years ago.
- The debt/assets ratio for ESPR has been reduced compared to a year ago.
2.2 Solvency
- ESPR has an Altman-Z score of -5.33. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -5.33, ESPR is doing worse than 64.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.33 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- ESPR has a Current Ratio of 1.00. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
- ESPR's Current ratio of 1.00 is on the low side compared to the rest of the industry. ESPR is outperformed by 85.34% of its industry peers.
- ESPR has a Quick Ratio of 1.00. This is a bad value and indicates that ESPR is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of ESPR (0.70) is worse than 85.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.87% over the past year.
- The Revenue has been growing slightly by 2.83% in the past year.
- The Revenue has been growing by 17.50% on average over the past years. This is quite good.
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
3.2 Future
- Based on estimates for the next years, ESPR will show a very strong growth in Earnings Per Share. The EPS will grow by 52.55% on average per year.
- Based on estimates for the next years, ESPR will show a very strong growth in Revenue. The Revenue will grow by 22.34% on average per year.
EPS Next Y80.08%
EPS Next 2Y58.58%
EPS Next 3Y42.44%
EPS Next 5Y52.55%
Revenue Next Year27.9%
Revenue Next 2Y10.33%
Revenue Next 3Y10.69%
Revenue Next 5Y22.34%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- ESPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 26.35, the valuation of ESPR can be described as expensive.
- Based on the Price/Forward Earnings ratio, ESPR is valued a bit cheaper than the industry average as 74.87% of the companies are valued more expensively.
- ESPR's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.97.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.35 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ESPR's earnings are expected to grow with 42.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.58%
EPS Next 3Y42.44%
5. Dividend
5.1 Amount
- No dividends for ESPR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.39
+0.07 (+2.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners46.36%
Inst Owner Change2.66%
Ins Owners0.49%
Ins Owner Change2.22%
Market Cap810.41M
Revenue(TTM)303.80M
Net Income(TTM)-105.83M
Analysts78.57
Price Target6.59 (94.4%)
Short Float %15.88%
Short Ratio6.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.6%
Min EPS beat(2)-183.71%
Max EPS beat(2)86.52%
EPS beat(4)2
Avg EPS beat(4)-25.67%
Min EPS beat(4)-183.71%
Max EPS beat(4)86.52%
EPS beat(8)4
Avg EPS beat(8)56.17%
EPS beat(12)7
Avg EPS beat(12)40.36%
EPS beat(16)10
Avg EPS beat(16)32.71%
Revenue beat(2)2
Avg Revenue beat(2)19.06%
Min Revenue beat(2)10.02%
Max Revenue beat(2)28.11%
Revenue beat(4)4
Avg Revenue beat(4)16.35%
Min Revenue beat(4)10.02%
Max Revenue beat(4)28.11%
Revenue beat(8)7
Avg Revenue beat(8)23.5%
Revenue beat(12)10
Avg Revenue beat(12)16.66%
Revenue beat(16)12
Avg Revenue beat(16)13.5%
PT rev (1m)0%
PT rev (3m)3.16%
EPS NQ rev (1m)-1.27%
EPS NQ rev (3m)5.28%
EPS NY rev (1m)37.4%
EPS NY rev (3m)-597.57%
Revenue NQ rev (1m)5.85%
Revenue NQ rev (3m)9.81%
Revenue NY rev (1m)1.1%
Revenue NY rev (3m)7.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.35 | ||
| P/S | 2.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)0.13
Fwd EY3.8%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.27
BVpS-1.89
TBVpS-1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% | ||
| FCFM | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score1
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | -5.33 |
F-Score1
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y80.08%
EPS Next 2Y58.58%
EPS Next 3Y42.44%
EPS Next 5Y52.55%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
Revenue Next Year27.9%
Revenue Next 2Y10.33%
Revenue Next 3Y10.69%
Revenue Next 5Y22.34%
EBIT growth 1Y-278.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-79.17%
EBIT Next 3Y18.69%
EBIT Next 5Y37.2%
FCF growth 1Y33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.79%
OCF growth 3YN/A
OCF growth 5YN/A
ESPERION THERAPEUTICS INC / ESPR FAQ
What is the ChartMill fundamental rating of ESPERION THERAPEUTICS INC (ESPR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ESPR.
What is the valuation status for ESPR stock?
ChartMill assigns a valuation rating of 3 / 10 to ESPERION THERAPEUTICS INC (ESPR). This can be considered as Overvalued.
Can you provide the profitability details for ESPERION THERAPEUTICS INC?
ESPERION THERAPEUTICS INC (ESPR) has a profitability rating of 1 / 10.
Can you provide the financial health for ESPR stock?
The financial health rating of ESPERION THERAPEUTICS INC (ESPR) is 1 / 10.
What is the expected EPS growth for ESPERION THERAPEUTICS INC (ESPR) stock?
The Earnings per Share (EPS) of ESPERION THERAPEUTICS INC (ESPR) is expected to grow by 80.08% in the next year.